<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101093791</journal-id>
<journal-id journal-id-type="pubmed-jr-id">30240</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Diab Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr. Diab. Rep.</journal-id>
<journal-title-group>
<journal-title>Current diabetes reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1534-4827</issn>
<issn pub-type="epub">1539-0829</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31250216</article-id>
<article-id pub-id-type="pmc">6894166</article-id>
<article-id pub-id-type="doi">10.1007/s11892-019-1175-9</article-id>
<article-id pub-id-type="manuscript">NIHMS1059753</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to <italic>KCNJ11</italic> Mutations</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Letourneau</surname>
<given-names>Lisa R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Greeley</surname>
<given-names>Siri Atma W.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<aff id="A1"><label>1</label>Section of Pediatric and Adult Endocrinology, Diabetes, and Metabolism Kovler Diabetes Center, University of Chicago, 5841 S. Maryland Ave., MC1027-N235, Chicago, IL 60637, USA</aff>
</contrib-group>
<author-notes>
<corresp id="CR1">Siri Atma W. Greeley, <email>sgreeley@peds.bsd.uchicago.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P37"><bold>Conflict of Interest</bold> The authors declare that they have no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>19</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<day>27</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>27</day>
<month>6</month>
<year>2020</year>
</pub-date>
<volume>19</volume>
<issue>8</issue>
<fpage>52</fpage>
<lpage>52</lpage>
<!--elocation-id from pubmed: 10.1007/s11892-019-1175-9-->
<abstract id="ABS1">
<sec id="S1">
<title>Purpose of Review</title>
<p id="P1">The goal of this review is to provide updates on the safety and efficacy of long-term sulfonylurea use in patients with <italic>KCNJ11</italic>-related diabetes. Publications from 2004 to the present were reviewed with an emphasis on literature since 2014.</p>
</sec>
<sec id="S2">
<title>Recent Findings</title>
<p id="P2">Sulfonylureas, often taken at high doses, have now been utilized effectively in <italic>KCNJ11</italic> patients for over 10 years. Mild-moderate hypoglycemia can occur, but in two studies with a combined 975 patient-years on sulfonylureas, no severe hypoglycemic events were reported. Improvements in neurodevelopment and motor function after transition to sulfonylureas continue to be described.</p>
</sec>
<sec id="S3">
<title>Summary</title>
<p id="P3">Sulfonylureas continue to be an effective, sustainable, and safe treatment for <italic>KCNJ11</italic>-related diabetes. Ongoing follow-up of patients in research registries will allow for deeper understanding of the facilitators and barriers to long-term sustainability. Further understanding of the effect of sulfonylurea on long-term neurodevelopmental outcomes, and the potential for adjunctive therapies, is needed.</p>
</sec>
</abstract>
<kwd-group>
<kwd>KCNJ11</kwd>
<kwd>Sulfonylurea</kwd>
<kwd>Glyburide</kwd>
<kwd>Neonatal diabetes</kwd>
<kwd>Monogenic diabetes</kwd>
<kwd>DEND syndrome</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>